Hsbc Global Res Upgrades Novo Nordisk A/S (NYSE:NVO) to Strong-Buy

Novo Nordisk A/S (NYSE:NVO - Get Free Report) was upgraded by Hsbc Global Res to a "strong-buy" rating in a report released on Monday,Zacks.com reports.

A number of other analysts have also commented on the company. Morgan Stanley began coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an "equal weight" rating for the company. Guggenheim downgraded Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. BMO Capital Markets restated a "market perform" rating and set a $64.00 target price (down previously from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. BNP Paribas began coverage on Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an "underperform" rating on the stock. Finally, Dbs Bank downgraded shares of Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, five have given a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $135.00.

Novo Nordisk A/S Stock Up 5.6 %

NYSE NVO traded up $3.67 during trading hours on Monday, reaching $69.27. 13,447,464 shares of the company's stock traded hands, compared to its average volume of 6,216,062. Novo Nordisk A/S has a 52-week low of $57.00 and a 52-week high of $148.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The firm has a 50-day simple moving average of $71.47 and a 200 day simple moving average of $87.99. The firm has a market cap of $310.85 billion, a PE ratio of 21.05, a PEG ratio of 0.90 and a beta of 0.61.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Institutional Investors Weigh In On Novo Nordisk A/S

Institutional investors and hedge funds have recently modified their holdings of the business. Saturna Capital Corp boosted its stake in shares of Novo Nordisk A/S by 1.6% during the first quarter. Saturna Capital Corp now owns 2,144,759 shares of the company's stock valued at $148,932,000 after purchasing an additional 32,811 shares during the period. Pecaut & CO. bought a new position in Novo Nordisk A/S in the 1st quarter worth about $1,499,000. Retirement Planning Co of New England Inc. increased its position in shares of Novo Nordisk A/S by 30.2% during the first quarter. Retirement Planning Co of New England Inc. now owns 13,085 shares of the company's stock worth $909,000 after acquiring an additional 3,036 shares during the period. Kingsview Wealth Management LLC raised its stake in shares of Novo Nordisk A/S by 9.3% during the first quarter. Kingsview Wealth Management LLC now owns 5,404 shares of the company's stock valued at $375,000 after acquiring an additional 461 shares in the last quarter. Finally, Bailard Inc. boosted its holdings in shares of Novo Nordisk A/S by 49.3% in the first quarter. Bailard Inc. now owns 12,968 shares of the company's stock valued at $900,000 after purchasing an additional 4,282 shares during the period. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.